OTC Obesity - France

Find Industry reports, Company profiles
ReportLinker and Market Statistics

>> Get this Report Now by email!

OTC Obesity - France
Published on April 2010

Report Summary

The main story in OTC obesity was the entrance of Alli by GlaxoSmithKline in 2009. According to trade press, this type of event only
occurs every 10 years in the pharmaceuticals market, the last time being the launch of Viagra in Rx form. The launch of Alli triggered
many articles in the media, heated reaction, criticism from experts and varied consumer opinion on Internet blogs and
messageboards, which ultimately resulted in free advertising for the GlaxoSmithKline brand.

Euromonitor International's OTC Obesity Products in France report offers a comprehensive guide to the size and shape of the market
at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to
2014 illustrate how the market is set to change.

Product coverage:

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report'
* Get a detailed picture of the Consumer Health industry;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market's major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online
information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network
of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help
drive informed strategic planning.

Table of Content

OTC Obesity in France
Euromonitor International
April 2010
List of Contents and Tables
Executive Summary
Consumer Health Lacks Dynamism
Launch of OTC Obesity Causes Controversy in Consumer Health
Consumer Health Characterised by Fragmented Competitive Environment
Chemists/pharmacies Continue To Dominate Retail Channels
Lack of Growth Will Cause Stagnation
Key Trends and Developments

OTC Obesity - France Page 1/6


Self-service: Old Habits Die Hard As Consumers Prefer Advice From Chemists/pharmacists
Consumer Health Battles Against 'alicaments', Highly Functional Foods
Stressful, Busy Lifestyles Influence Natural Choices
Fat Fighting - OTC Obesity Category Launched With New Product Alli
Consumer Health Is Fragmented But Targeted
Market Indicators
Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009
Table 2 Life Expectancy at Birth 2004-2009
Market Data
Table 3 Sales of Consumer Health by Sector: Value 2004-2009
Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009
Table 5 Consumer Health Company Shares by Value 2005-2009
Table 6 Consumer Health Brand Shares by Value 2006-2009
Table 7 Penetration of Private Label by Sector 2004-2009
Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009
Table 9 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009
Table 10 Forecast Sales of Consumer Health by Sector: Value 2009-2014
Table 11 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014
Appendix
OTC Registration and Classification
Advertising
Packaging and Labelling
Distribution
Vitamins and Dietary Supplements Registration and Classification
EU Legislation
Self-medication/self-care and Preventive Medicine
Generics
Switches
Summary 1 OTC Healthcare Switches 2007-2009
Definitions
Sector and Subsector Definitions
Summary 2 Research Sources
Arkopharma Sa, Laboratoires Pharmaceutiques
Strategic Direction
Key Facts
Summary 3 Laboratoires Pharmaceutiques Arkopharma SA: Key Facts
Summary 4 Laboratoires Pharmaceutiques Arkopharma SA: Operational Indicators
Company Background
Competitive Positioning
Summary 5 Laboratoires Pharmaceutiques Arkopharma SA: Competitive Position 2009
Beaufour-ipsen SA
Strategic Direction
Key Facts
Summary 6 Beaufour-Ipsen SA: Key Facts
Summary 7 Beaufour-Ipsen SA: Operational Indicators
Company Background
Production
Summary 8 Beaufour-Ipsen SA: Production Statistics
Summary 9 Beaufour-Ipsen SA: Competitive Position 2009



Cooper SA
Strategic Direction
Key Facts
Summary 10 Cooper SA: Key Facts
Summary 11 Cooper SA: Operational Indicators
Company Background
Production
Summary 12 Cooper SA: Production Statistics
Summary 13 Cooper SA: Competitive Position 2009
GlaxoSmithKline Santé Grand Public Sas
Strategic Direction
Key Facts
Summary 14 GlaxoSmithKline Santé Grand Public SAS: Key Facts
Summary 15 GlaxoSmithKline Santé Grand Public SAS: Operational Indicators
Company Background
Production
Summary 16 GlaxoSmithKline France: Production Statistics
Summary 17 GlaxoSmithKline Santé Grand Public SAS: Competitive Position 2009
Juva Santé, Groupe
Strategic Direction
Key Facts
Summary 18 Laboratoires Juva Santé: Key Facts
Company Background
Production
Summary 20 Laboratoires Juva Santé: Production Statistics
Summary 21 Laboratoires Juva Santé: Competitive Position 2009
Laboratoires Mcneil
Strategic Direction
Key Facts
Summary 22 Laboratoires McNeil: Key Facts
Summary 23 Laboratoires McNeil: Operational Indicators
Company Background
Summary 24 Laboratoires McNeil: Competitive Position 2009
Pierre Fabre Sa, Laboratoires
Strategic Direction
Key Facts
Summary 25 Laboratoires Pierre Fabre SA: Key Facts
Summary 26 Laboratoires Pierre Fabre SA: Operational Indicators
Company Background
Production
Summary 27 Laboratoires Pierre Fabre SA: Production Statistics
Summary 28 Laboratoires Pierre Fabre SA: Competitive Position 2009
Théraplix SA
Strategic Direction
Key Facts



Summary 29 Théraplix SA: Key Facts
Company Background
Summary 30 Théraplix SA: Competitive Position 2009
Upsa, Laboratoires
Strategic Direction
Key Facts
Summary 31 Laboratoires UPSA: Key Facts
Summary 32 Laboratoires UPSA: Operational Indicators
Company Background
Production
Summary 33 Laboratoires UPSA: Production Statistics
Summary 34 Laboratoires UPSA: Competitive Position 2009
Urgo, Laboratoires
Strategic Direction
Key Facts
Summary 35 Laboratoires Urgo: Key Facts
Summary 36 Laboratoires Urgo: Operational Indicators
Company Background
Production
Summary 37 Laboratoires Urgo: Competitive Position 2009
Trends
Category Data
Table 12 Sales of OTC Obesity: Value 2009
Table 13 OTC Obesity Company Shares by Value 2005-2009
Table 14 OTC Obesity Brand Shares by Value 2006-2009
Table 15 Forecast Sales of OTC Obesity: Value 2009-2014
Table 16 Forecast Sales of OTC Obesity: % Value Growth 2009-2014



Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

OTC Obesity - France

Product Formats
Please select the product formats and the quantity you require.

Digital Copy--USD 957.60 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________



Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


OTC Obesity - France

Recommandé

Recommandé

Contenu connexe

Plus de ReportLinker.com

Plus de ReportLinker.com (20)

Dernier

Dernier (20)

OTC Obesity - France